Article info
Respiratory research
Original research
Sphingolipid, fatty acid and phospholipid metabolites are associated with disease severity and mTOR inhibition in lymphangioleiomyomatosis
- Correspondence to Professor Simon R Johnson, Division of Respiratory Medicine, NIHR Biomedical Research Centre and Nottingham Molecular Pathology Node, University of Nottingham, Nottingham NG7 2UH, UK; simon.johnson{at}nottingham.ac.uk
Citation
Sphingolipid, fatty acid and phospholipid metabolites are associated with disease severity and mTOR inhibition in lymphangioleiomyomatosis
Publication history
- Received October 23, 2019
- Revised March 26, 2020
- Accepted April 16, 2020
- First published May 28, 2020.
Online issue publication
July 15, 2020
Article Versions
- Previous version (28 May 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.